NEWS

Reata Pharma receives orphan drug designation for Omaveloxolone

Thursday, Sep 14, 2017

Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma.

Reata Pharmaceuticals Inc - ‍FDA granted orphan designation to Omaveloxolone for treatment of stage IIb through IV malignant melanoma.

 

Source: reuters.com

Other News